选择性环氧化酶-2（COX-2）抑制剂与心血管事件的潜在风险。

Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.

作者信息

Mukherjee Debabrata

机构信息

Division of Cardiology, University Hospital, University of Michigan Health System, B1-F245, 1500 East Medical Center Drive, Ann Arbor, MI 48103-0022, USA.

出版信息

Biochem Pharmacol. 2002 Mar 1;63(5):817-21. doi: 10.1016/s0006-2952(02)00842-0.

DOI:10.1016/s0006-2952(02)00842-0

PMID:11911832

Abstract

Selective cyclooxygenase-2 (COX-2) inhibitors were developed as a response to the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents (NSAIDs). However, COX-2 inhibitors decrease vascular prostacyclin (PGI(2)) production and may disrupt the homeostatic mechanisms that limit the effects of platelet activation. Basic and clinical data raise concerns about a potential prothrombotic effect of this class of drugs. The widespread popularity of these agents mandates their prospective evaluation in patients with cardiovascular diseases or who are at risk for cardiovascular events.

摘要

选择性环氧化酶-2（COX-2）抑制剂是为应对传统非甾体抗炎药（NSAIDs）的胃肠道毒性而研发的。然而，COX-2抑制剂会减少血管前列环素（PGI₂）的生成，并可能破坏限制血小板活化作用的稳态机制。基础和临床数据引发了对这类药物潜在促血栓形成作用的担忧。这些药物的广泛应用要求对心血管疾病患者或有心血管事件风险的患者进行前瞻性评估。